On December 23, 2021, Reneo Pharmaceuticals, Inc. entered into a Transition, Separation and Consulting Agreement with Wendy Johnson, in connection with her previously announced resignation from the Company. The Agreement provides that until December 31, 2021 (the “Separation Date”), Ms. Johnson will continue to serve as the Company’s Chief Business Officer, a role which she undertook upon the hiring and appointment of Ashley F. Hall, J.D. to the position of Chief Development Officer.